VECT-HORUS announces the signing of a scientific

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
VECT-HORUS announces the signing of a scientific collaboration agreement with SERVIER

MARSEILLE, France, June 16, 2015 (GLOBE NEWSWIRE) -- VECT-HORUS, a biotechnology company that designs and develops peptide vectors that facilitate the delivery of drugs or imaging agents, notably in the brain, is announcing today the signing of a scientific collaboration agreement with SERVIER. The companies did not disclose the financial terms of this agreement. This collaboration is part of VECT-HORUS' framework strategy, which is to use its proprietary technology to enter into R&D agreements with biopharmaceutical companies to generate patentable new chemical entities (NCEs), based on the vectorization of their drug candidates.

This collaboration agreement with SERVIER, first independent French pharmaceutical research company, reflects the growing interest in the drug delivery platform developed by VECT-HORUS. " This research program, based on receptor targeting to facilitates delivery of therapeutic agents to the brain, is a true recognition of our scientific strategy ", says Alexandre Tokay, co-founder and CEO of VECT-HORUS.

The main objective of VECT-HORUS' innovative technology is to address drug delivery across the vascular system of the brain called the blood brain barrier (BBB) that impedes most drugs from accessing the nervous tissue. VECT-HORUS thus designs and develops peptide vectors that facilitate the delivery of drugs or imaging agents into different tissues, including nervous tissue, thereby allowing the treatment of CNS disorders, which represent a high unmet medical need and are already the second largest therapeutic market worldwide.

The scientific strategy of the company is based on the principle that the BBB is not only a physical barrier that must be crossed, but also a functional barrier whose natural transport mechanisms may be advantageously used to deliver drugs into the brain. The peptide-vectors developed by VECT-HORUS use endogenous transport mechanisms to facilitate the passage of drugs or imaging agents across the BBB, into the pathological brain

About SERVIER

SERVIER is an independent French research-based pharmaceutical company. Its development is driven by the pursuit of innovation in the therapeutic areas of cardiovascular, metabolic, central nervous system, psychiatric, bone, muscle and joint diseases, as well as cancer.

In 2014, the company recorded a turnover of 4 billion euros.

92% of SERVIER medicines are prescribed outside of France.

28% of turnover from SERVIER drugs was reinvested in Research and Development in 2014.

With a strong international presence in 146 countries, SERVIER employs more than 21,400 people worldwide.

More information is available at: www.servier.com

About VECT-HORUS

VECT-HORUS is a French biotechnology company that designs and develops peptide-vectors to facilitate the delivery of drugs or imaging agents toward the brain and other organs. By combining pharmaceutical agents to peptide vectors, VECT-HORUS enables their transport across the BBB that significantly impedes brain delivery of most drugs.

From this perspective, VECT-HORUS has identified and validated highly specific and stable vectors protected by several families of patents and patent applications.

The company has already demonstrated proof of concept of the technology in animal models by vectorizing different molecules, among them the endogenous neuropeptide neurotensin, which is currently in regulatory preclinical studies. The technology has also enabled the signing of a scientific collaboration agreement with SANOFI in the field of neurodegenerative diseases.

Founded in 2005, VECT-HORUS is a spin-off from the CNRS-AMU NICN laboratory directed by Dr. Michel Khrestchatisky. Its founders are Alexandre Tokay, Chairman, and Michel Khrestchatisky, Scientific Counsel. VECT-HORUS has 17 employees, mostly in R&D.

VECT-HORUS is identified by the CNRS as one of the 15 success stories among 1,000 spinoffs from its laboratories.

More about VECT-HORUS at www.vect-horus.com

Contacts

ATCG Press Marie PUVIEUX +33 6 10 54 36 72 (France) Jean-Mehdi GRANGEON +33 (0)6 62 22 00 24 (UK/USA) presse@atcg-partners.com

VECT-HORUS Alexandre TOKAY CEO and co-founder + 33 6 30 40 36 95 alexandre.tokay@vect-horus.com

PR VECT-HORUS & SERVIER http://hugin.info/164689/R/1928674/692548.pdf

HUG#1928674

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 160

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 297

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 258

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 308

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 266

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 304

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 85

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 85

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 225

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

The Booming Ethylene Vinyl Acetate Market: Insights and Trends

Updated Category News Views 114

Understanding the Growth of the Ethylene Vinyl Acetate Market As we delve into the dynamic landscape of the Ethylene Vinyl Acetate (EVA) market, it's clear that the demand for sustainable solutions is reshaping this sector. Recently valued at USD 11.0 billion, the market is projected to reach an impressive USD 19.2 billion by 2032, reflecting a compound annual growth rate...

Continue Reading
FETV Lassoing Nostalgia with 'Rawhide' Marathon

Updated Category News Views 35

FETV Brings 'Rawhide' Back for a July 4th Ride If anybody still had doubts about classic TV riding back into our living rooms and kicking up dust, FETV's got a surprise for them. This Independence Day, FETV's all geared up to bring the legendary western series, Rawhide, galloping back onto our screens. A weekend full of cattle drives and cowboy grit is exactly the kind of...

Continue Reading
China-Pakistani Lab Aims to Tackle Earthquake Disasters

Updated Category News Views 29

When the ground decides to play havoc, it takes a teamwork of the ages to put things back together. The China-Pakistan Belt and Road Joint Laboratory on Smart Disaster Prevention has taken on the task of preventing such chaos, especially for regions that flirt regularly with disaster, like Pakistan. From Surviving to Saving The memory of the 7.8-magnitude quake that...

Continue Reading
Investors Alert: Charter Communications Faces Legal Scrutiny

Updated Category News Views 149

Legal Concerns Surrounding Charter Communications Shamis & Gentile, P.A. has initiated an investigation into possible claims on behalf of investors of Charter Communications, Inc. (CHTR). This inquiry aims to assist those who may have suffered losses due to the actions of the company and its executives. Understanding the Investigation Investors in Charter Communications...

Continue Reading
Bumble's Options Activity: Insights and Market Trends

Updated Category News Views 336

Understanding Bumble's Recent Options Activity Recent analyses indicate that substantial financial entities are making bold moves in the options market surrounding Bumble Inc (NASDAQ: BMBL). A deep dive into options trading patterns reveals noteworthy insights about trader sentiment and market expectations. Analyzing Trader Sentiment The current options trades showcase a...

Continue Reading